Two mutants of human immunodeficiency virus (HIV) reverse transcriptase (RT), Tyr181 to Cys and Leu100 to lie, have been prepared and characterized by use of various inhibitors. As compared to~~type RT the mutant RT's had lower KeatlK m values. The K m values were lower with heteropolymeric than with homopo-Iymeric template-primers. Inhibition by phosphonoformate was of mixed type with both wild-type and mutant RT's and the mutants were less sensitive to phosphonoformate than the wild type RT. The nonnucleoside RT inhibitors 9-CI-TIBO and L-697,661 gave a non-competitive inhibition with respect to substrate of the wild type RT. The mutant RT's were inhibited at higher concentrations, showing a mixed type of inhibition with respect to substrate. ddGTP caused a competitive inhibition of wild type and mutant RT's with respect to substrate, RT preparations with different mutations are useful in rapidly characterizing the interaction between various inhibitors and HIV RT and thus facilitate the development of new inhibitors.
Introduction
The urgent need for drugs against infections with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) has brought forward many new antiviral compounds, some of which have reached clinical use, but more are required because of toxicity and/or resistance development. The main target for inhibitors of HIV replication has so far been the HIV reverse transcriptase (R1). (For reviews, see Oberg, 1988; De Clercq, 1991 Hammer, 1992a, 1992b) . Several non-nucleoside inhibitors acting directly on HIV-1 RT have recently been found (Pauwels et al., 1990; Merluzzi et al., 1990; Goldman et al., 1991; Baba et al., 1991; Romero et aI., 1991; Camarasa et el., 1992) . These non-nucleoside inhibitors seem to cause a more rapid resistance development than the nucleoside analogues which inhibit HIV RT after intracellular phosphorylation to triphosphates (Smith et el., 1987; Larder et al., 1989a Larder et al., , 1989b Larder et al., , 1991 Richman et el., 1991; Nunberg et aI., 1991; Mellors et al., 1992; St. Clair et al., 1991; Gao et aI., 1992; D. Richman, personal communication; M. S. Saag, personal communication) .
Since development of resistance is emerging as a major problem in the development of new anti-HIV drugs, we have started to prepare different HIV-1 RT mutants to use these purified enzymes as tools to rapidly characterize the interaction between new inhibitors and RT. The choice of the first mutants was based on published findings that the mutation Tyr181 to Cys in HIV-1 RT causes resistance to TIBO and similar compounds (Nunberg et aI., 1991) and on our own finding that development of resistance to TIBO in cell culture also can be due to a Leu100 to lie mutation (L. Vrang, personal communication) . Inhibitors of three different types were used to characterize these mutant enzymes and compare them to RT from wild type virus.
Results

Characterization of wild type and mutant RT preparations
The enzymatic properties of RT (wt), RT (lIe100) and RT (Cys181) were compared with respect to catalytic efficiency, KeatlK m, and substrate affinity, K m, using different template-primers and the results are summarized in Tables 1 and 2. The initial velocity of each enzyme was measured at saturating amounts of template-primers and at different substrate concentrations. The reactions were of apparent first order following Michaelis-Menten kinetics. Double reciprocal plots of substrate concentration vs. rate gave the constants K m and Kcal (Vmax = K eal [Ej) .
With one exception, all template-primers and substrates used showed the highest KcatlK m for RT (wt) and the lowest for the RT (lle100) mutant. In most cases the K m values were lower when heteropolymeric templateprimers were used than when homo polymers were used. The only large difference in K m value between the three different enzymes for anyone template-primer was observed for (dC),.,-{dGh2-18 when the RT (wt) showed a nearly 10-fold higher K m value than the K m values for the mutants.
The dependence on KCI and Mg 2 + did not reveal any differences in optima between the three RT preparations (not shown).
Inhibition by PFA
The pyrophosphate analogue PFA (phosphonoformate, foscarnet) was used as an example of a non-competitive inhibitor of RT (Vrang and Oberg, 1986) .
As can be seen in Fig. 1 PFA caused a mixed type of inhibition of RT (lIe1 00) and this type of inhibition was also observed for RT (wt) and RT (Cys181) (not shown) when (rC)n'(dG)12-18 was used as primer-template and dGTP as substrate. The kinetic constants were determined by linear regression analysis and are presented in Table 3 .
Both RT (Cys181) and RT (lIe1 00) were partially resistant to PFA as compared to the sensitivity of RT (wt).
Inhibition by 9-01-TlBG and L-697,661
The effects of the two direct-acting non-nucleoside RT inhibitors, 9-CI-TIBO (Pauwels et al., 1990; Desbyser et aI., 1991) and L-697,661 on the different RT's using (rC)n'(dGh2-18 as primer-template are described in Tables 4 and 5. The lIe1 00 mutation caused a more pronounced resistance to 9-CI-TIBO than to L-697,661 and the Cys181 mutant was relatively more resistant than the lIe100 mutant to L-697,661, while the reverse was true for 9-CI-TIBO. 9-CI-TIBO caused a mixed type of non-competitive and competitive inhibition as shown in Fig. 2 for RT (lIe100) when (rC)n'(dG)12-18 and dGTP were used. However, the inhibition of RT (wt) by L-697,661 showed a non-competitive pattern at low concentrations and a mixed pattern at high concentrations of the compound . (Fig. 3a ). The inhibition of RT (lIe100) and RT (Cys181) showed a mixed type of non-cornpetltlve and competitive inhibition (Fig.  3b ,c) which may reflect the requirement for high concentrations of the compound to achieve inhibition of these mutant HIV-RT's.
Inhibition by ddGTP
The guanosine triphosphate analog, ddGTP, gave a competitive inhibition with respect to the incorporation of dGMP into (rC)n'(dG)12-18 with the wild type as well as the mutant RT's as exemplified in Fig. 4 . The kinetic constants are shown in Table 6 . No large differences in the inhibitory constants (K i ) of ddGTP or ratio K/K m was observed when the different RT's were compared.
Discussion
A very detailed knowledge about the structure of HIV-1 RT is forthcoming (Jacobo-Molina et el. 1991; Kohlstaedt et aI., 1992; Lindborg, 1992) and will facilitate the design of new RT inhibitors. The development of resistance towards RT inhibitors is likely to be a considerable clinical problem for many drugs but it will also give useful information about the interaction between inhibitors and RT and possibilities to overcome resistance. Constructing and preparing HIV RT mutants will give useful tools for studying the interaction between inhibitors and various parts of HIV RT. The two mutants made here were HIV-1 RT (Cys181), which has been reported to confer resistance of HIV 3.0 l/dGMP(pmol-l ) Slopes and intercepts the mutants were lower than for the wild type enzyme (Tables 1 and 2) . Merluzzi et at. (1990) reported a K cat value of 0.25 S-1 which is higher than that of 0.082 S-1 observed with our HIV-1 RT (wt) preparation when dGTP and (rC)n'{dGh2-18 were used in the assay. A K cat value of 0.028-1 was observed by Kopp et at. (1991) using HIV-1 RT (wt) heteropolymer RNA template and dGTP which is somewhat lower than the value of 0.0478-1 in Table 2 . The K cat value for HIV-1 RT (wt) seen when dTTP was used with the same template-primer was 0.08s-1 which is higher than that of 0.025 S-1 found by Reardon and Miller (1990) .
In general the K cat values were lower when heteropolymers were used. The K m value of 0.22/-l-M for HIV-1 RT (wt) using {rC)n·{dGh2-18 as primer-template and dGTP as substrate corresponds to the value of 0.57/-l-M reported by Merluzzi Table 3 . Inhibition of wild type and mutant HIV-1 RT activities by PFA. (Nunberg et el., 1991; Mellors et a/., 1992) , and HIV-1 RT (lIe100) which decreases the sensitivity of HIV-1 to 9-CI-TIBO and L-697,661 in cell cultures (L.
Vrang et el., personal communication). The two mutant enzymes and HIV-1 RT (wt) could be prepared in high purity (>90%) according to previously described methods (Unge et a/., 1990; Bhikhabhai et a/., 1992) .
Comparing the enzymatic properties of RT (wt), RT (lIe100) and RT (Cys181) revealed that the K cat values for et at. (1990) but not to that of 5 J.LM found by Debyser et al. (1991) . The specificity constants Kcat/K m were lower for the mutant RT's than for wt enzyme, showing a decrease in catalytic efficacy. If this decrease in catalytic efficacy has any implications for the rate of viral replication in vivo is not known, but is of considerable interest.
The decrease in K m when changing from homopolymer to heteropolymer template-primer corresponds to earlier observations with HIV-1 RT (wt) (Reardon and Miller, 1990; Kopp et st., 1991; Parker et a/., 1991) . As observed by Reardon and Miller (1990) and Kopp et at. (1991) the overall efficiency of catalysis, KcatlK m , differed little between homo-and heteropolymeric template-primers (Table 1 and 2).
PFA has earlier been reported (Goldman et el., 1991) to displace from HIV-1 RTa compound, L-697,639 and to be mutually exclusive with L-696,229 (Goldman et sl., 1992) , both compounds being very similar to L-697,661. However, RT (Asn1 03, Cys181) was not reported to differ from RT (wt) in its sensitivity to PFA, nor was there any difference in inhibition by PFA of viral replication in cell culture when HIV-1 (Asn103, Cys181) and wt virus were compared . Mellors et at. (1992) found similar sensitivities in cell culture to PFA of HIV-1 (wt) and HIV-1 (Cys181), selected for resistance to BI-RG-587. Recombinant RT (wt) and RT (Cys181) were also found to have similar sensitivities to PFA (Mellors et a/., 1992) . Debyser et at. (1992) did not see any increased resistance to PFA of the TIBO-resistant HIV-1 RT mutant 188 Tyr to Leu and Nunberg et al. (1991) have suggested that the PPi site is distinct from the L-697,661 binding site but that they communicate allosterically.
However, the present results (Table 3) show a 2-fold decrease in inhibition by PFA when the Cys181 and the lIe1 00 mutations were introduced in HIV-1 RT. This would be in accordance with the displacement results from Nunberg et al. (1992) and the overlapping of pyridinone and PFA binding to RT . The increase in resistance to PFA (Table 3) caused by the lIe100 and Cys181 mutations could be explained by their proximity to the area proposed by Larder et at. (1987) and Lindborg (1992) to be involved in PPi binding. According to the crystal structure (Kohlstaedt et el., 1992) the nonnucleoside binding site is found close to but not overlapping with the alleged substrate-binding (pyrophosphatebinding) site. It is not clear why the present results showing a decrease in sensitivity to PFA differ from the earlier published, but differences in template-primer could possibly influence the result.
The two non-nucleoside inhibitors, 9-CI-TIBO and L-697,661, showed somewhat different effects againstthe two resistant RT's (Tables 4 and 5) . HIV-1 RT(Cys181) had a similar resistance to 9-CI-TIBO and to L-697,661 while HIV-1 RT (lIe100)was more resistant to 9-CI-TIBO than to L-697,661.
A non-competitive type of inhibition with respect to substrate was observed for 9-CI-TIBO and L-697,661 for RT (wt) and, a mixed type of inhibition at higher concentrations, for RT (lIe100) and RT (Cys181) (Figs 2 and 3) . This corresponds with the type of mechanism earlier reported using RT(wt) (Goldman et a/., , 1992 Debyser et aI., 1991) . No kinetic study on mutant RT has been reported but Debyser et al. (1992) found the weak inhibition of RT from simian immunodeficiency virus (SIV) by TIBO to be competitive to dGTP.
The RT (lIe100) mutant was selected in cell culture from MT-4 cells infected with HIV-1 in the presence of 9-CI-TIBO and as expected this new mutant was also resistant to L-697,661.
The inhibition by ddGTP of both wt and the two mutant RT's was competitive with respect to dGTP (Fig. 4) and the inhibition was similar (Table 6 ). Using three other TIBOresistant RT's with mutations in position 188, Debyser et al. (1992) found both slight increases and decreases in the IC 5 0 values for ddGTP.
Several more mutant RT's will be required to investigate rapidly inhibition by new inhibitors in order to deliniate the interaction between the inhibitor and the enzyme. However, the two mutants constructed here could be used to observe the overlapping interaction between phosphonoforrnate and two non-nucleoside analogues and differences in inhibition of these two non-nucleoside analogues. Further RT mutants are being prepared to improve the possibilities to characterize the similarities and differences in interaction between new inhibitors and HIV-1 RT.
Materials and Experimental procedures
Materials Q-Sepharose, Heparin Sepharose and S-Sepharose were from Pharmacia, Uppsala, Sweden.
The synthetic template-primers (rA)n'(dl)12-18, (rCln-(dGh2-18 and (dC)n'(dGh2-18 were purchased from Pharmacia LKB Biotechnology AB, Uppsala, Sweden.
16S and 23S ribosomal RNA templates and specific 15-mer primer (5'-TAACCTIGCGGCCGT-3') were generous gifts from Dr Richard Jaskunas, Eli Lilly Co. (Indianapolis,IN) and the hybrid was prepared by the procedure of White et al. (1991) .
Activated calf thymus DNA was prepared by treating calf thymus DNA with pancreatic DNase at room temperature for 15min using the procedure of Baril et al. (1977) .
All template-primer preparations were diluted to 1 mg ml-1 as stock solutions in 10fLM Tris·HCI, pH 7.9 and 100fLM NaCI, and stored in aliquots at -20°C.
Tritium-labelled deoxyribonucleotides, dGTP and dTIP, were obtained from Amersham, UK. The specific activities were 37 Ci rnmol"" and 11OCi mmor", respectively. The four deoxyribonucleoside triphosphates (dATP,dCTP, dTIP, dGTP) , phospheneformate (PFA) and 2' ,3'-dideoxyguanosine triphosphate (ddGTP) were purchased from Sigma Chemicals. 9-CI-TIBO was purchased from Pharmatech Int. Inc. (NJ) L-697,661 (3-{[(4,7-dichloro-1 ,3-benzoxazol-2-yl)methyl]amino}-5-ethyl-6-methylpyridin-2(1 H)-one) was kindly supplied by Dr M. E. Goldman at Merck, Sharp and Dohme Research Laboratories (Rahway, NY) . Stock solutions of 9-CI-TIBO and L-697,661 were made in dimethyl sulphoxide (DMSO).
Construction of expression system
Escherichia coli strains TG1 and HB101 were used forthe plasmid constructions. Escherichia coli strain BL21(DE3) was used for expression. Restriction enzymes,T4 DNAligase and calf intestine phosphatase were obtained from Boehringer Mannheim. Polymerase chain reaction (PCR) was performed with Taq DNA polymerase and reaction components from Perkin Elmer Cetus, The cloning vector bluescript KS+ and the VCS-M 13 helper phage were from Stratagene and the expression vector pET11 a from Novagene. The DNA sequencing was performed according to Wahlberg et al. (1992a) , with some modification since the starting material was purified plasmid DNA. The plasmid (10ng) was amplified with primers RIT134-137(Wahlberget al., 1992a) in a nested approach and immobilized to paramagnetic beads (Wahlberg et al., 1992b) (DynalAs, Oslo, Norway) . A T7 polymerase sequencing protocol (Hultman et aI., 1991) was used and the fragments were analysed on an automated laser fluorescent DNA sequencer (Pharmacia LKB Biotechnology AB, Uppsala, Sweden).
The RT gene was isolated by PCR technique from the plasmid pN1OE (Unge et al., 1990) .The primers in the PCR reaction were designed so that a Nde I site containing the start codon ATG was introduced at the 5' terminus and Bam HI site at the 3' terminus of the fragment. The PCR fragment was blunt end ligated into the cloning vector bluescript KS+ at the EcoRV site. The new construct was called pRT.BS. Single stranded DNA was isolated from pRT.BS by the use of the VCS-M13 helper phage, and oligodirected site specific mutagenesis was done according to the method by Sayers et al. (1988) . Leu100 (ITA) was mutated to lie (ATA) and Tyr181 (TAl) was mutated to Cys (TGl) by single base exchange. The expression vectors for the two mutant forms, RT(lIe100) and RT(Cys181) were constructed by isolation of the corresponding Ndel-BamHI fragments from the mutated pRT.BS and ligated to pET11 a which previously had been treated with Ndel and BamHI.
Preparation of RT
Expression was performed in the E. coli strain BL21(DE3). Transformed cells were grown to OD = 1.0 before induction with IPTG (Studier et al., 1990) . The cells were harvested after 3h of induction.
Wild type and mutant RTwere purified essentially as described previously (Unge et al., 1990; Bhikhabhai et al., 1992) , The supernatants of the ceillysates were precipitated with ammonium sulphate and dialysed. The RT material was 99% pure, as judged by SDS polyacrylamide gel electrophoresis, after a sequence of three chromatographic steps: Q-Sepharose, Heparin Sepharose and S-Sepharose.
Enzyme assay
The RT assay using the homopolymeric template-primers (rA)n'(dl)12-18, (rC)n,(dG)12-18 and (dC)n·(dGh2-18 contained 100mM Tris·HCI, pH 7.8, 100mM KCI, 4mM DTI, 4mM MgCI 2, 250fL9 mr" bovine serum albumine. The template-primer concentrations were saturated at 100ng rnr' , 25 fL9 rnr' and 20 fL9 mr", respectively. The DMSO concentration in the assays, originating from dissolved inhibitors, was 1%.
The assay conditions using the heteropolymeric templateprimers, 10/Lg mr' ribosomal RNA-oligo DNA and 125/Lg rnr' activated calf thymus DNA were the same as for homopolymeric template-primers with the exception that 50 mM KCI and 6 mM MgCb were used for the RNA-template, and 100mM KCI and 20mM MgCb for the DNA-template.
The reactions were started by addition of enzyme to the final concentrations of 250 ng ml-1 RT (wt); 300 ng mr ' RT (lIe1 00) and
200ng rnr' RT (Cys181), except when using (rA)n·(d1)12-18 as template-primer when 100 ng mr' of RT (wt) and 200 ng mr' of RT (mutants) were used. After 30 min incubation at 3rC, 45/L1 reaction mixture was spotted onto filter discs (Munktell, Sweden). The discs were placed in 5% (vlv) ice cold trichloroacetic acid with 20 mMsodium pyrophosphate and washed three times with this solution and then three times with ethanol. The incorporation of the substrate into the template was linear over this time and was determined by liquid scintillation counting.
